News and Press Releases
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
3 December 2025 -- Amsterdam, The Netherlands and Massachusetts, US -- VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2025
Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate
2 December 2025 -- Clermont-Ferrand, France -- Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025
Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
1 December 2025 -- Zurich, Switzerland -- Xlife Sciences AG, together with saniva diagnostics GmbH, today announced a landmark achievement: NeuroMex is the world’s first certified and clinically validated medical device for...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: December 1, 2025
Annovis Announces FDA Meeting to Discuss Parkinson’s Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer’s Disease Study
18 November 2025 -- Pennsylvania, US -- Annovis Bio, Inc, a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 18, 2025
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
Financing supports execution of early-stage clinical trials for Anocca’s lead programme VIDAR-1, powered by the Company’s leading-edge R&D platform, to target pancreatic cancer VIDAR-1 is the first non-viral gene-edited TCR-T...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: August 18, 2025
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer’s Patient Treated with Intranasal Foralumab
9 May 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3...
Category: Biotechnology, Other, Pharmaceutical
Posted: May 9, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Leqembi ▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease in the UK is validated for evaluation by the MHRA
Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment The...
Category: Other, Pharmaceutical
Posted: April 30, 2025
PLL Therapeutics enrolls first patient in phase I/II trial of drug candidate PLL001 for Amyotrophic Lateral Sclerosis (ALS)
Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo 140 ALS patients will participate in second stage of study to...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025
10 Avenue Roger Lapébie 33140 Villenave d’Ornon France
HEALEY ALS Platform Trial Preparation Shows Positive Respiratory Outcome of NUZ-001
Updates to HEALEY ALS Platform Trial Master Protocol have been made to enhance the potential of establishing a clinically meaningful outcome for patients, including: Treatment period extended from 24 to...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia
Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round
Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of...
Category: Drug Discovery
Posted: January 17, 2025
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
Mr. Satter’s Extensive Investment, Company-Building, and Transaction Experience Strengthens Alzheon’s Board Leadership Valiltramiprosate/ALZ-801 Has Potential to Become the First Oral Agent to Slow Alzheimer’s Pathology in Patients APOLLOE4 Pivotal Phase...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 7, 2025
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 17, 2024
ILC Therapeutics completes £2.5m financing and bolsters C-suite
Owain Millington appointed CEO, Julie Bailey appointed CFO and Dawn Firmin appointed COO Financing to support pre-clinical development of ILCT’s two lead assets 11 September 2024 -- Glasgow, UK --...
Category:
Posted: September 13, 2024
Asceneuron Secures $100m Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK...
Category: Biotechnology, Clinical Trials, Other
Posted: July 16, 2024
Asceneuron SA, EPFL Innovation Park, Bâtiment B, CH-1015 Lausanne, Switzerland
